Immune‐Related Adverse Events in a Patient With Burkitt’s Lymphoma During PD‐1 Immune Consolidation Therapy: A Case Report
A patient with Burkitt's lymphoma developed upper gastrointestinal adverse events during immune consolidation therapy following chemotherapy combined with autologous stem cell transplantation. Subsequent administration of vedolizumab as adjunctive therapy resulted in improvement of the patient's symptoms. This case is expected to provide a reference for the expanded application of PD-1 inhibitors in non-Hodgkin's lymphoma.
Authors
- Qi Zhang (ORCID: https://orcid.org/0000-0002-2440-4451)
- Chaoyong James Yang (ORCID: https://orcid.org/0000-0002-2374-5342)
- Yicheng Zhang (ORCID: https://orcid.org/0000-0003-4300-0900)
- Yi Xiao (ORCID: https://orcid.org/0000-0001-7274-6774)
- Xiaojian Zhu (ORCID: https://orcid.org/0000-0002-2782-0311)
- Fankai Meng (ORCID: https://orcid.org/0000-0002-6838-3955)
Institutions
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Case Reports in Hematology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1155/crh/9967011
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China